Prosecution Insights
Last updated: November 12, 2026
Application No. 18/720,258

SOLID DIAMIDE AND BIFENTHRIN FORMULATION FOR CONTROLLING INVERTEBRATE PESTS

Non-Final OA §103
Filed
Jun 14, 2024
Priority
Dec 16, 2021 — provisional 63/290,255 +1 more
Examiner
PATEL, SAGAR S
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fmc Ip Technology GmbH
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
363 granted / 480 resolved
+15.6% vs TC avg
Strong +35% interview lift
Without
With
+35.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
29 currently pending
Career history
507
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 8 – 12, 14 – 19 and newly added claims 20 – 24 are pending. Claims 1, 8 – 12 and 14 – 17 are rejected. Claims 18 – 24 are withdrawn. Election/ Restriction Applicant's election with traverse of Group I (claims 1, 8 – 12 and 14 – 17) in the reply filed on August 28, 2026 is acknowledged. Claims 2 – 7 and 13 have been cancelled. The traversal is on the grounds that the prior art Fuilong CN 111837172 A does not disclose a solid granule formulation having the claimed low concentrations of bifenthrin and chlorantraniliprole and the claimed solid carrier, as recited in the amended claims. On page 6, lines 18-23, Applicant note that Embodiment 3 of Fuilong is the “only disclosed composition comprising an amount of bifenthrin within the range in presently amended claim 1 but the amount of chlorantraniliprole in this embodiment (0.6 wt%) is higher, while also containing less solid carrier, than the range in presently amended claim 1. On page 6, lines 24-28, Applicant further state the benefits of the compositions in the present application towards environmental sustainability, while displaying excellent pesticidal activity. Thus, the solid granule formulation in the instant application makes a contribution over the teachings of Fuilong. This is not found persuasive because Embodiment Example 3 teaches 0.4% by weight of bifenthrin, which falls within the range of concentration as disclosed in the instant claims. Further, Example 3 also teaches 0.6% by weight of chlorantraniliprole, which is slightly outside the range of concentration as disclosed in the instant claims. Thus, the technical feature of the solid composition comprising low concentrations of bifenthrin and chlorantraniliprole is not considered a special technical feature in view of the teachings of Fuilong. The requirement is still deemed proper and is therefore made FINAL. New claims 20 – 24 are directed to processes for preparing a solid pesticidal composition comprising bifenthrin and a diamide insecticide. The scope of this invention was not previously presented and the claims are directed to a new invention. Thus, claims 20 – 24 are restricted under new Group III. Further, Applicant has specifically elected chlorantraniliprole as the diamide insecticide. Examination: Claims 1, 8 – 12 and 14 – 17 read on the elected invention/ species. The elected invention is not allowable over the prior art. Claims 18 – 24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Priority PNG media_image1.png 62 388 media_image1.png Greyscale Information Disclosure Statement The information disclosure statement (IDS) submitted on June 14, 2024 and May 19, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement are being considered by the examiner. Claim Objections Claims 9 – 10 and 12 are objected to because of the following informalities: Claim 9, page 2 line 31: The limitation “about 0.40 %wt. bifenthrin, and” is grammatically incorrect because it improperly recites the term “and”. The term “and” should only be recited between the last two limitations. See, page 3, line 3. In order to overcome the objection, Applicant may amend to delete the term “and”. Claim 10, lines 2 – 6. The limitation “… drying agent selected from the group consisting of calcium silicate, calcium carbonate, … microcrystalline cellulose, attapulgite clay, and combinations of any of the foregoing” is grammatically incorrect because it does not recite proper Markush group language and singular form for the group of alternatives. The term “combinations” should not be included as part of the Markush group language and refers to the drying agent, which is in a singular form. In order to overcome the objection, Applicant may amend the limitation as follows: “… drying agent selected from the group consisting of calcium silicate, calcium carbonate, … microcrystalline cellulose, and attapulgite clay, or a combination Claim 12, lines 2 – 5. The limitation “one sticking agent selected from the group consisting of polyvinyl alcohols, polyvinyl acetates, acrylic acids, polyacryclic acid, polyvinyl pyrrolidone, polyethylene oxide, copolymers of acrylic acid, salts thereof, and combinations of any of the foregoing” is grammatically incorrect because it does not recite proper Markush group language and singular form for the group of alternatives. In order to overcome the objection, Applicant may amend the limitation as follows: “one sticking agent selected from the group consisting of polyvinyl alcohol acetate acid and copolymers of acrylic acid, a salt or a combination. Appropriate correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 8 – 12 and 14 – 17 are rejected under 35 U.S.C. 103 as being unpatentable over Fuilong CN 111837172 A, cited in IDS dated June 14, 2024, as evidenced by English translation of CN 111837172 A, https://worldwide.espacenet.com/publicationDetails/description? CC=CN&NR=111838172A&KC=A&FT=D&ND=3&date=20201030&DB=EPODOC&locale=en_EP, Accessed on September 28, 2026. Determining the scope and contents of the prior art Fuilong teaches a compound insecticide (pesticidal composition in the instant claims) comprising bifenthrin, chlorantraniliprole and excipients (adjuvant in the instant claims). See attached English translation, paragraph [0007]. The insecticide is prepared into granules by granulation. See, paragraph [0013]. Specifically, Fuilong teaches an insecticide comprising 0.4% by weight of bifenthrin, 0.6% by weight of chlorantraniliprole and excipients. The excipients contains of 3% by weight of binder, 3% by weight of surfactant, and a balance filler. Granules of the insecticide are prepared using a coating method. See, e.g., paragraph [0033]. Ascertaining the differences between the prior art and the claims at issue Compared to claims 1 and 8 – 9, Fuilong does not explicitly teach: The concentration of diamide insecticide is from 0.19 wt.% to 0.31 wt.% (specifically, about 0.25 wt.% claimed in claim 9) of total weight of the composition, The solid carrier is present at a concentration of at least 95.0 wt.% (specifically, at least 97 wt.% in claim 9) of the total weight of the composition, About 0.05 wt.% to about 0.35 wt.% (specifically, 0.10 wt.% to about 0.30 wt.% in claim 9) of a drying agent, About 0.15 wt.% to about 0.50 wt.% (specifically, 0.20 wt.% to about 0.40 wt.% in claim 9) of a solvent, and About 0.05 wt.% to about 0.25 wt.% (specifically, 0.10 wt.% to about 0.20 wt.% in claim 9) of a sticking agent. Rationale for a prima face case of obviousness According to MPEP §2141(III), two of the rationales in the KSR decision states “(E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success… (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention”. KSR, 550 U.S. at 418, 82 USPQ2d at 1396. While Fuilong does not specifically teach the exact concentrations of chlorantraniliprole, solid carrier, drying agent, solvent and sticking agent, it does teach that the weight ratio of bifenthrin to chlorantraniliprole can be selected from the range of 0.1–10 : 0.01–5.0, and the total weight of bifenthrin and chlorantraniliprole can also be adjusted in the range of 0.11 – 15% of the total weight of the composition, and the remaining weight is excipients. See, e.g., paragraph [0007]. Further, Fuilong teaches chlorantraniliprole has strong penetrability, and its activity is 10-100 times higher than other products against target pests, which can cause mating disorders in insects and moths. See, e.g., paragraph [0041]. MPEP §2144.05(II)(A) states: “Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)”. A person having ordinary skill in the art would have been motivated to perform routine experimentation, such as optimization of the concentrations of chlorantraniliprole, solid carrier, drying agent, solvent and sticking agent and preparation protocol of the solid pesticidal composition. The purpose of the routine experimentation would have been to determine which concentrations of chlorantraniliprole, solid carrier, drying agent, solvent and sticking agent would be optimal to prepare the granular compositions and successfully provide the best insecticidal properties in combination with bifenthrin. With respect to claims 10 – 12, Fuilong teaches that the excipients comprise binder, surfactant and balance filler. Fuilong teaches that the balance filler is light calcium carbonate (drying agent in the instant claim). See, e.g., paragraph [0011]. Surfactant can be paraffin in any proportion. See, e.g., paragraph [0033]. Paraffin qualifies as a hydrotreated light petroleum distillate (according to Official Notice). The binder (sticking agent in the instant claim) is selected from one or mixture of corn starch, flour, and maltodextrin. See, e.g., paragraph [0035]. With respect to claims 14 – 17, please note the limitation “for protecting an organism from an invertebrate parasitic pest” is intended use limitations as governed by MPEP §2111.02(II). Intended use limitations are interpreted based on the structural limitations they impart to the invention. In this case, the intended use only requires the solid pesticidal composition for protecting an organism from an invertebrate parasitic pest, but does not impart any specific limitations to the structure. Based on the teachings of Fuilong, the effective amount of the composition is capable for oral administration and protecting an organism from an invertebrate parasistic pest. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sagar Patel whose telephone number is (571)272-1317. The examiner can normally be reached Monday - Friday: 9am to 5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached at (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Sagar Patel/Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jun 14, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790348
INTRACELLULAR ATP ENHANCER
3y 5m to grant Granted Nov 10, 2026
Patent 12780816
SOLID FORMS OF A BENZTHIAZOLE-PIPERAZINYL-OXAZOLE COMPOUND AND METHODS OF USE THEREOF
2y 3m to grant Granted Nov 03, 2026
Patent 12751953
MRGX Receptor Antagonists
6y 11m to grant Granted Oct 06, 2026
Patent 12740950
SHORT CONJUGATED OLIGOELECTROLYTESAND ANTIBIOTICS
4y 4m to grant Granted Sep 22, 2026
Patent 12741933
SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS
3y 5m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+35.2%)
Low
PTA Risk
Based on 480 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month